Biofrontera Inc. (NASDAQ:BFRI – Get Free Report) was the target of a large increase in short interest in May. As of May 31st, there was short interest totalling 15,400 shares, an increase of 94.9% from the May 15th total of 7,900 shares. Based on an average trading volume of 101,600 shares, the days-to-cover ratio is currently 0.2 days. Currently, 0.5% of the company’s stock are short sold.
Hedge Funds Weigh In On Biofrontera
An institutional investor recently bought a new position in Biofrontera stock. Rosalind Advisors Inc. acquired a new position in Biofrontera Inc. (NASDAQ:BFRI – Free Report) in the first quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund acquired 504,261 shares of the company’s stock, valued at approximately $777,000. Biofrontera comprises 0.7% of Rosalind Advisors Inc.’s portfolio, making the stock its 27th largest position. Rosalind Advisors Inc. owned about 9.91% of Biofrontera at the end of the most recent reporting period. 10.08% of the stock is owned by institutional investors and hedge funds.
Biofrontera Price Performance
Shares of BFRI stock traded up $0.09 during trading hours on Friday, hitting $1.09. 32,709 shares of the company’s stock traded hands, compared to its average volume of 33,581. The stock’s fifty day simple moving average is $1.41 and its two-hundred day simple moving average is $1.74. Biofrontera has a 12-month low of $0.61 and a 12-month high of $13.42.
Biofrontera Company Profile
Biofrontera Inc, a biopharmaceutical company, engages in the commercialization of pharmaceutical products for the treatment of dermatological conditions in the United States. The company's products are used for the treatment of actinic keratoses, which are pre-cancerous skin lesions, as well as impetigo, a bacterial skin infection.
Read More
- Five stocks we like better than Biofrontera
- When to Sell a Stock for Profit or Loss
- MarketBeat Week in Review – 6/10 – 6/14
- The Role Economic Reports Play in a Successful Investment Strategy
- Top 5 High-Performance Cryptocurrency ETFs to Watch
- ETF Screener: Uses and Step-by-Step Guide
- 3 Stocks That Plummeted After the Post-Fed Speech Crash
Receive News & Ratings for Biofrontera Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Biofrontera and related companies with MarketBeat.com's FREE daily email newsletter.